Translational Medicine Communications will cease to be published by BioMed Central as of 31st December 2024. BMC will continue to host an archive of all articles published in Translational Medicine Communications and it will remain fully searchable via the BMC website. You can view all the published articles here.
Announcement
Articles
-
-
Plasma proteomes of acute myeloid leukemia patients treated with transfusions reveal signatures of inflammation and hemostatic dysregulation
-
Pathogenesis of human atheroma necrotic core: degradation of connective tissue fibers and possible involvement of cathepsin K
-
Thiamine deficiency underlies persistent gut dysbiosis and inflammation in people living with HIV on antiretroviral therapy
-
Primed for death: prognostic role of BH3--only proteins in breast cancer therapy: a systematic and meta-analysis review
-
Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles
-
The role of serotonin and diet in the prevalence of irritable bowel syndrome: a systematic review
-
Behavioural symptoms of mental health disorder such as depression among young people using Instagram: a systematic review
-
Synergy of melanin and vitamin-D may play a fundamental role in preventing SARS-CoV-2 infections and halt COVID-19 by inactivating furin protease
-
Cell Banking of HEK293T cell line for clinical-grade lentiviral particles manufacturing
Aims and scope
Translational Medicine Communications will cease to be published by BioMed Central as of 31st December 2024. BMC will continue to host an archive of all articles published in Translational Medicine Communications and it will remain fully searchable via the BMC website. You can view all the published articles here.
Translational Medicine Communications is an interdisciplinary forum for all scientifically valid research from across translational medicine. We publish research that focuses on the biology of disease, as well as preclinical and basic research that is closely associated with medicine. Translational Medicine Communications will also consider reviews, methodology articles, protocols and commentaries.
Our aim is to improve transparency and reproducibility within translational medicine, which is why we consider research papers regardless of outcome or significance of findings, as well as protocols for future research. We aim to serve the translational science community by publishing all scientifically valid and technically sound articles and we are dedicated to facilitating the communication between basic and clinical science.
Editor-in-Chief: Francesco Marincola, Sonata Therapeutics, USA
Franco Marincola is the Chief Scientific Officer of Sonata Therapeutics. Franco brings over 30 years of research and development experience in immunology, oncology and cell therapy to Sonata.
Most recently, Franco served as Senior Vice President and Global Head of Research at Kite Pharma where he led the research organization to identify novel therapies for hematologic malignancies and solid tumors. Prior to Kite, he was President and Chief Scientific Officer at Refuge Biotechnologies, where he developed research strategies for adoptive cell therapy products and led therapeutic programs based on nuclease deactivated CRISPR circuits. Prior to Refuge, Franco was Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre.
Before joining the biopharma industry, Franco spent more than two decades at the National Institutes of Health (NIH) and National Cancer Institute (NCI), most recently as a tenured senior investigator in cancer immunotherapy and biomarker research and as Chief Infectious Disease and Immunogenetics Investigator at the NIH Clinical Center.
Franco is the former President of the Society for Immunotherapy of Cancer (SITC). He currently serves as Editor-in-Chief for multiple peer-reviewed publications, including Journal of Translational Medicine, Translational Medicine Communications, and Immunotherapy, and is the author of more than 600 peer-reviewed publications.
Franco received his M.D. from the University of Milan and completed his residency at Stanford University.
Annual Journal Metrics
-
Speed 2023
Submission to first editorial decision (median days): 9
Submission to acceptance (median days): 75Usage 2023
Downloads: 221,911
Altmetric mentions: 163